Central government directs state regulators to enhance surveillance over GLP-1 drug promotion. Approved GLP-1 drugs are only for Type 2 diabetes and specific weight management. Advisories were issued to manufacturers and drug controllers regarding product information. Regulators must monitor supply chains and take action against diversion. Advertising platforms will be monitored for non-compliant promotions and violations.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.